NCT06780826

A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

A Simulated RCT Study on the Efficacy of Atezolizumab Combined with Chemotherapy Versus Placebo Combined with Chemotherapy in Small Cell Lung Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,430 (estimated)
• Sponsor: Shanghai Pulmonary Hospital, Shanghai, China · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter phase III simulated RCT study aimed to compare the efficacy and safety of atezolizumab combined with chemotherapy versus placebo combined with chemotherapy in small cell lung cancer.

Conditions

• Lung Cancer, Small Cell

Interventions

Type	Name	Description
DRUG	Atezolizumab	Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
DRUG	Etoposide	Etoposide,intravenous infusion, 100mg/m,21 days per cycle
DRUG	Carboplatin	carboplatin,intravenous infusion, AUC=5, 21 days per cycle.

Timeline

• Start date: 2024-08-28
• Primary completion: 2025-06-30
• Completion: 2025-09-30
• First posted: 2025-01-17
• Last updated: 2025-01-17

Locations

1 site across 1 country: China